Pharmaxis: A Star Performer at Commercialization Crossroads
9B06M093
-
- $3.99
-
- $3.99
Publisher Description
Pharmaxis is a new biotechnology venture based in Sydney, Australia. The case brings to light the important stages in the growth of the company and the commercialization decisions the company faced. It also highlights both the uniqueness of some of the managing team's decisions and their understanding of the industry. The case underscores the point that good decision-making can overcome apparent barriers to growth. The company is now at a key decision point. It needs to determine the best approach to commercialize its first diagnostic product. The wrong decision could waste scarce financial resources, divert the time of managers and researchers, and jeopardize the reputation of the firm with potential investors.
Is Cost Containment Impacting Pharmaceutical Innovation?
2008
Challenge of Access to Oncology Drugs in Canada
2009
Alpes S.A.: A Joint Venture Proposal (A)
2006
Orchid Chemicals & Pharmaceuticals Limited: Managing the Value Chain Transformation
2006
A&D Pharma: Unaudited Financial Statement for the 12 Months Ended 31 December 2009
2010
CMS Expects to Launch CMS024 for the Treatment of Primary Liver Carcinoma Three Years Ahead of Plan in 2013
2011